[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia]

I.H. Dufva; J. Stentoft; H.C. Hasselbalch; Ole Weis Bjerrum

[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia]

I.H. Dufva, J. Stentoft, H.C. Hasselbalch, Ole Weis Bjerrum

Research output: Contribution to journal › Journal article › Research › peer-review

1 Citation (Scopus)

Abstract

Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understanding the biology of the tyrosin kinase led to targeted therapy, inhibiting the ATP-binding site by a small molecule--imatinib (Glivec). A novel 2nd generation tyrosin kinase inhibitor--dasatinib (Sprycel)--is now available in cases of insufficient response or intolerance to imatinib
Udgivelsesdato: 2008/1/28

Original language	Danish
Journal	Ugeskrift for læger
Volume	170
Issue number	5
Pages (from-to)	331-333
Number of pages	2
ISSN	0041-5782
Publication status	Published - 2008

Cite this

@article{26e958d097c211de8bc9000ea68e967b,

title = "[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia]",

abstract = "Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understanding the biology of the tyrosin kinase led to targeted therapy, inhibiting the ATP-binding site by a small molecule--imatinib (Glivec). A novel 2nd generation tyrosin kinase inhibitor--dasatinib (Sprycel)--is now available in cases of insufficient response or intolerance to imatinib Udgivelsesdato: 2008/1/28",

author = "I.H. Dufva and J. Stentoft and H.C. Hasselbalch and Bjerrum, {Ole Weis}",

year = "2008",

language = "Dansk",

volume = "170",

pages = "331--333",

journal = "Ugeskrift for l{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

TY - JOUR

T1 - [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia]

AU - Dufva, I.H.

AU - Stentoft, J.

AU - Hasselbalch, H.C.

AU - Bjerrum, Ole Weis

PY - 2008

Y1 - 2008

N2 - Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understanding the biology of the tyrosin kinase led to targeted therapy, inhibiting the ATP-binding site by a small molecule--imatinib (Glivec). A novel 2nd generation tyrosin kinase inhibitor--dasatinib (Sprycel)--is now available in cases of insufficient response or intolerance to imatinib Udgivelsesdato: 2008/1/28

AB - Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understanding the biology of the tyrosin kinase led to targeted therapy, inhibiting the ATP-binding site by a small molecule--imatinib (Glivec). A novel 2nd generation tyrosin kinase inhibitor--dasatinib (Sprycel)--is now available in cases of insufficient response or intolerance to imatinib Udgivelsesdato: 2008/1/28

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 170

SP - 331

EP - 333

JO - Ugeskrift for læger

JF - Ugeskrift for læger

IS - 5

ER -